Fully Integrated Platform

Ascletis is an innovative R&D driven biotech with two commercial products and listed on Hong Kong Stock Exchange (Ascletis, 1672.HK). Ascletis’ mission is to address unmet medical needs in three therapeutic areas: viral, cancer and fatty liver diseases. Led by a management team with deep expertise and a proven track record, Ascletis has developed a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization.

Antibody-based Immunotherapy

ASC22,PD-L1 antibody for HBV, first-in-class, subcutaneous, room temperature stable,phase 2 ready.

First/Best-in-Class Small Molecules

ASC40, first-in-class FASN inhibitor for NASH, phase 2. ASC09, best-in-class HIV protease inhibitor with unprecedented genetic barrier, phase 2.


ASC06, first systematically delivered, dual-targeting siRNA for liver cancer, phase 1.

Imagine what you could do at Ascletis

Our greatest assets are our employees. Ascletis is an equal opportunity employer and focused on providing a positive work environment where courageous innovation is encouraged and expected.

Our mission is to become a world-class biotechnology company addressing unmet medical needs in three therapeutic areas: anti-viral, cancer and fatty liver disease, for the patients in China and worldwide. Our highly talented team of researchers and professionals who passionately share in this common mission.

We offer competitive salaries and benefits that reward employees for their contribution to the company. If you’re interested in learning more about what we have to offer, please email your CV to hr@ascletis.com. We will look to match any current and upcoming openings to your area of expertise.

手机投注开户_线上银河注册,12bet首页备用登录 怎么注册eth钱包 莱特币今日价格走势图 澳盈娱乐注册 奥门皇冠影院 正版游戏下载平台中文游戏 真人赌钱游戏平台